200 Penobscot Drive
United States - Map
Codexis, Inc. engages in the production of custom industrial enzymes for use in the pharmaceutical, biofuel, and chemical production. The company offers Codex Biocatalyst Panels and Kits to pharmaceutical companies that are engaged in drug development and the marketing of approved drugs to allow them to screen and identify possible enzymatic manufacturing processes for their drug candidates and their marketed products. It also provides enzyme screening, enzyme optimization, and enzyme services, as well as supplies intermediates and active pharmaceutical ingredients to pharmaceutical companies. In addition, the company develops CodeXyme cellulase enzymes to convert cellulosic biomass, a non-food plant material into affordable sugars, which could then be converted into renewable fuels and chemicals; and CodeXol detergent alcohols used to manufacture surfactants, which are used as cleaning ingredients in consumer products, such as shampoos, liquid soaps, and laundry detergents. It intends to market CodeXyme cellulase enzymes to chemicals manufacturers; and CodeXol detergent alcohols as a drop-in substitute for the detergent alcohols market. The company has collaboration with Purolite Corporation to develop and market enzymes for the pharmaceutical industry. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.
|Codexis, Inc.’s ISS Governance QuickScore as of Jul 1, 2013 is 10. The pillar scores are Audit: 10; Board: 6; Shareholder Rights: 10; Compensation: 10.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. John J. Nicols ,
Chief Exec. Officer, Pres and Director
|Mr. David D. O'Toole ,
Chief Financial Officer, Principal Accounting Officer and Sr. VP
|Mr. Douglas T. Sheehy J.D.,
Sr. VP, Gen. Counsel and Corp. Sec.
|Mr. Matthew Tobin D.Phil,
Sr. VP of R&D
|Dr. Alan Shaw Ph.D.,
|Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|